Skip to content
Screener

Cytek Biosciences, Inc. CTKB Operating Income

Operating Income at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$663M-24.8%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$2.09B—
Danaher logo
DanaherDHR
$1.13B+48.3%
Revvity logo
RevvityRVTY
$89.32M-1.6%
Agilent Technologies logo
Agilent TechnologiesA
$399M+33.0%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
-$34.62M-74.9%

Other financials

Income statement

See full
Revenue$48.1M+5.6%
Gross profit$28.3M+18.7%
Net income-$12.2M-118%
EPS (diluted)-$0.09-125%

Balance sheet

See full
Cash & equivalents$73.8M-2.2%
Total debt$17.0M-6.6%
Total equity$322.0M-14.7%
Total assets$446.9M-9.4%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+40.5%
Free cash flow-$849.0K+42.2%

Valuation

See full
Market cap$545.93M+25.6%
Enterprise value$489.11M+29.2%
P/S2.6×+0.4×

Profitability

See full
Gross margin53.2%-1.2pp
Operating margin-21.6%—
Net margin-39%—
FCF margin-5.8%-11.4pp

Returns & leverage

See full
Return on equity-23%—
Debt / equity0.1×0.0×
Current ratio4.5×-0.7×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053496
(In thousands, except share and per share data)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Sales and marketing13,17412,13424,82024,643
General and administrative16,82513,53135,29226,429
Total operating expenses39,74034,49179,45769,622
Loss from operations(11,400)(10,624)(29,863)(25,598)
Other income (expense):
Interest expense(281)(414)(543)(705)
Interest income8195551,6061,063
Other income (expense), net(781)3,708(216)7,199

Item 1. Consolidated Financial Statements (Unaudited)

FAQ

What is Cytek Biosciences, Inc.'s operating income?
Cytek Biosciences, Inc. (CTKB) reported operating income of -$11.4M in Q2 2026.
How has Cytek Biosciences, Inc.'s operating income changed year-over-year?
Cytek Biosciences, Inc.'s operating income decreased by 7.3% year-over-year, from -$10.62M to -$11.4M.
What is the long-term trend for Cytek Biosciences, Inc.'s operating income?
Over 3 years (2021 to 2025), Cytek Biosciences, Inc.'s operating income has grown at a 64.0% compound annual growth rate (CAGR), from $9.16M to -$40.39M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Cytek Biosciences, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude